T. Rowe Price Associates’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $127K | Hold |
26,765
| – | – | ﹤0.01% | 2846 |
|
|
2025
Q1 | $123K | Buy |
26,765
+4,500
| +20% | +$20.7K | ﹤0.01% | 2780 |
|
|
2024
Q4 | $107K | Buy |
22,265
+3,370
| +18% | +$16.2K | ﹤0.01% | 2814 |
|
|
2024
Q3 | $89K | Buy |
18,895
+1,865
| +11% | +$8.79K | ﹤0.01% | 2842 |
|
|
2024
Q2 | $97K | Buy |
17,030
+1,206
| +8% | +$6.87K | ﹤0.01% | 2764 |
|
|
2024
Q1 | $66K | Buy |
15,824
+2,425
| +18% | +$10.1K | ﹤0.01% | 2836 |
|
|
2023
Q4 | $57K | Buy |
13,399
+1,244
| +10% | +$5.29K | ﹤0.01% | 2789 |
|
|
2023
Q3 | $53K | Buy |
12,155
+726
| +6% | +$3.17K | ﹤0.01% | 2766 |
|
|
2023
Q2 | $76K | Buy |
11,429
+1,049
| +10% | +$6.98K | ﹤0.01% | 2735 |
|
|
2023
Q1 | $71K | Buy |
+10,380
| New | +$71K | ﹤0.01% | 2741 |
|
|
2015
Q2 | – | Sell |
-365,628
| Closed | -$3.4M | – | 2557 |
|
|
2015
Q1 | $3.4M | Sell |
365,628
-4,209,593
| -92% | -$39.1M | ﹤0.01% | 1523 |
|
|
2014
Q4 | $65.5M | Buy |
4,575,221
+470,700
| +11% | +$6.74M | 0.01% | 744 |
|
|
2014
Q3 | $42.6M | Buy |
4,104,521
+677,730
| +20% | +$7.03M | 0.01% | 889 |
|
|
2014
Q2 | $55.4M | Buy |
3,426,791
+1,674,910
| +96% | +$27.1M | 0.01% | 831 |
|
|
2014
Q1 | $28.5M | Buy |
1,751,881
+543,480
| +45% | +$8.83M | 0.01% | 1017 |
|
|
2013
Q4 | $15M | Buy |
1,208,401
+1,185,201
| +5,109% | +$14.7M | ﹤0.01% | 1175 |
|
|
2013
Q3 | $255K | Sell |
23,200
-5,100
| -18% | -$56.1K | ﹤0.01% | 2173 |
|
|
2013
Q2 | $229K | Buy |
+28,300
| New | +$229K | ﹤0.01% | 2163 |
|